Background: Mad1 and Mad2 are constituents of the spindle-assembly checkpoint, a device coupling the loss of sister-chromatid cohesion at anaphase to the completion of microtubule attachment of the sister chromatids at metaphase. Fluorescence recovery after photobleaching (FRAP) revealed that the interaction of cytosolic Mad2 with kinetochores is highly dynamic, suggesting a mechanism of catalytic activation of Mad2 at kinetochores followed by its release in a complex with Cdc20. The recruitment of cytosolic Mad2 to kinetochores has been attributed to a stable receptor composed of a distinct pool of Mad2 tightly bound to Mad1. Whether specifically this interaction accounts for the kinetochore dynamics of Mad2 is currently unknown. Results: To gain a precise molecular understanding of the interaction of Mad2 with kinetochores, we reconstituted the putative Mad2 kinetochore receptor and developed a kinetochore recruitment assay with purified components. When analyzed by FRAP in vitro, this system faithfully reproduced the previously described in vivo dynamics of Mad2, providing an unequivocal molecular account of the interaction of Mad2 with kinetochores. Using the same approach, we dissected the mechanism of action of p31 comet , a spindle-assembly checkpoint inhibitor. Conclusions: In vitro FRAP is a widely applicable approach to dissecting the molecular bases of the interaction of a macromolecule with an insoluble cellular scaffold. The combination of in vitro fluorescence recovery after photobleaching with additional fluorescence-based assays in vitro can be used to unveil mechanism, stoichiometry, and kinetic parameters of a
Introduction
Fluorescence recovery after photobleaching (FRAP) is an imaging technique that takes advantage of the fact that fluorophores can be irreversibly photobleached within a given area by using a focused beam of light [1, 2] . If biological molecules containing bleached fluorophores leave the area, they will be replaced with nonbleached fluorescent molecules. This allows kinetics measurements and the determination of the fraction of recovery, which can reveal the existence of a spatially fixed, immobile fraction of the ligand that cannot be replaced with ligand bound to unbleached fluorophores from solution [1, 2] . Among FRAP's several insightful applications is the possibility of studying the kinetics of binding of macromolecules to various cellular compartments and organelles [1, 2] . A limitation of these studies, however, is that the relationship between the kinetic FRAP measurements and the specific molecular interactions on which they are based usually remains unknown. This is because in most cases the identity of the macromolecules involved and their regulation are not known in sufficient detail. A possible strategy to overcome this limitation consists in (1) making an assumption about the identity of the molecular players in the interaction, (2) reconstituting the interaction in vitro with purified components, (3) measuring the dynamic properties of this reconstituted system, and (4) assessing their similarity with values determined in vivo [2] . Arguably, this approach would have widespread beneficial consequences on our ability to model complex biological systems [3, 4] .
Here, we provide an account of our attempts to apply this strategy to the study of the interaction of the spindle-assembly checkpoint (SAC) protein Mad2 with kinetochores, because this has been extensively investigated by FRAP in vivo [5] [6] [7] [8] . Kinetochores are complex protein scaffolds that assemble on centromeric DNA. They mediate the attachment of microtubules during mitosis and recruit the SAC proteins to monitor this process [9] . For coordinating the onset of anaphase with the completion of the attachment process, Mad2 is believed to be activated at unattached kinetochores to sequester Cdc20, its target in the checkpoint [10, 11] . Mad2 has two stable conformations differing for the position of a 50 residue segment at its C terminus [12, 13] . The closed conformation (C-Mad2) is observed when Mad2 binds Cdc20 [12, 13] . C-Mad2 is also observed in the complex of Mad2 with Mad1, a SAC protein that is necessary for Mad2 kinetochore recruitment [13] [14] [15] [16] [17] [18] . The open conformation of Mad2 (O-Mad2) is the physiological state of cytosolic Mad2 in the absence of Mad1 or Cdc20 [19, 20] .
As summarized in Table 1A -1E, FRAP experiments on Mad2 provided apparently conflicting results. Two studies (Table 1B and 1C) using either transient transfection of GFP-Mad2 or direct injection of Alexa-fluor-488-labeled Mad2 in live cells prior to mitosis reported near to 100% recovery of Mad2 kinetochore fluorescence [5, 6] . Another study (Table 1A) exploiting stable cell lines expressing YFP-Mad2 revealed instead that the rapidly exchanging pool of Mad2 accounts for w50% of kinetochore Mad2, whereas another w50% resides stably at these structures [7] . All studies, on the other hand, found that Mad1 is mainly a stable kinetochore resident in mitosis [5, 7] . These observations led to the hypothesis that a complex of Mad1 with Mad2 (Mad1:Mad2), accounting for the immobile Mad1 and Mad2 fractions, might be responsible for the recruitment of a mobile fraction of Mad2 from the cytosol [7] . The ''Mad2 template'' hypothesis [19] tried to provide a more detailed molecular description of this reaction by proposing that the cytosolic fraction of Mad2, which adopts the O-Mad2 conformation, is recruited to the kinetochores by the C-Mad2 conformer in the Mad1:C-Mad2 complex. According to the ''Mad2 template'' model, the ability of O-Mad2 to form a conformational dimer with C-Mad2 is the critical interaction for kinetochore recruitment of cytosolic O-Mad2.
The significance of the model will be discussed thoroughly later in this paper.
We reasoned that if the molecular description of the Mad2 kinetochore cycle provided by the ''Mad2 template'' model were correct, a system of purified components and defined composition containing O-Mad2 and the Mad1:C-Mad2 complex should display dynamic properties comparable to those observed in living cells. Ideally, this system might also provide a convincing explanation for the discrepancies in recovery efficiencies in different experiments that we have detailed above. Here we provide an account of our findings.
Results
The binding of Mad2 to the Mad1:Mad2 complex can be visualized by using size-exclusion chromatography (SEC). Recombinant wild-type human Mad2 (Mad2 wt ) was covalently labeled with Alexa-fluor-488 (abbreviated as Alexa, Figure 1A ). When stoichiometric amounts of Alexa-Mad2 and the unlabeled recombinant Mad1: Mad2 complex (whose elution profiles are shown in Figures 1A and 1B, respectively) are mixed, the Alexa-Mad2 signal is incorporated in a high-molecular complex with Mad1:Mad2 ( Figure 1C) . Identical results were obtained if CFP-Mad2 was used instead of Alexa-Mad2 (Figures S1A and S1B in the Supplemental Data available online).
Our recently formulated ''Mad2 template'' hypothesis [19] suggests that the binding reaction causing the shift of Alexa-Mad2 consists of the binding of O-Mad2 (drafted from the Alexa-labeled population) to a stable C-Mad2 conformer in the Mad1:Mad2 complex ( Figure  1D ). The hypothesis predicts that the two populations of Mad2 shown in Figure 1D do not exchange subunits, because C-Mad2 does not dissociate from Mad1. Consequently, the ''Mad2 template'' model predicts that the kinetochore cycle of Mad2 is caused by the binding of O-Mad2 to the C-Mad2 subunits contained in the Mad1:Mad2 complex.
We tested this prediction by using a strategy of in vitro FRAP. For this, we reconstituted a fluorescent version of the Mad1:C-Mad2 kinetochore complex by bacterial coexpression of CFP-Mad2 and biotinylated Mad1 and immobilized it on streptavidin beads. Beads containing Mad1:CFP-Mad2 were brightly fluorescent when imaged with a confocal microscope. Although the complex is noncovalent, fluorescence intensity remained constant in the absence of soluble CFP-Mad2 ( Figure 2A) . Thus, the Mad1:Mad2 tetramer is sturdy, and the rate of dissociation of CFP-Mad2 from Mad1 is negligible [12, 21] . After CFP bleaching in a small area, no recovery of fluorescence was observed, showing that the immobilized sample does not undergo lateral diffusion at the beads' surface ( Figure 2A ; see Figures S1 and S2 for additional controls).
Checkpoint response requires both kinetochorebound and cytosolic Mad2 [17] . To analyze the interaction of ''cytosolic'' Mad2 with ''kinetochores,'' we added CFP-Mad2 to the medium containing the Mad1:CFP-CMad2 beads. In the presence of soluble CFP-Mad2, we observed rapid recovery of 38% 6 5% of the prebleaching fluorescence ( Figure 2B and Table 1F ). The time-dependency of the recovery was nicely fitted with a single exponential function (1 2 e 2kt ) with a recovery halftime (t 1/2 ) of 4.2 s. As in living cells [5] [6] [7] [8] , there is therefore a single type of Mad2 binding site on our in vitro ''kinetochores.''
Since CFP-C-Mad2 does not dissociate from Mad1 (Figure 2A ), the w40% recovery observed in this experiment must be due to CFP-O-Mad2 cycling between solution and Mad1:C-Mad2. If CFP-O-Mad2 replaced bleached CFP-C-Mad2 directly bound to Mad1, near to full recovery would be predicted. To confirm this, we applied two consecutive rounds of photobleaching to the same area of the beads ( Figure 3A and Table  1M ). Whereas the first photobleaching was followed by w40% recovery, the second event resulted in 75% 6 5% recovery, about twice the value observed after the first photobleaching. The half-time of recovery for the Two consecutive photobleaching events were imposed on the same area. Recovery after the first photobleaching event is w38% 6 5%. After the second event, recovery approaches w75% 6 5%. Statistics for this experiment are in Table 1M . (B) If C-Mad2 is unlabeled, recovery approaches w87% 6 8% of the initial fluorescence already after the first bleaching event. See Table 1G (Table 1H) .
second event (4.6 s), however, was essentially identical to that of the first event, indicating that recovery is due to the same binding reaction. Thus, the Mad1-bound CFP-C-Mad2 fraction bleached after the first laser pulse cannot be replaced with fluorescent CFP-Mad2. The second FRAP experiment is analogous to carrying out an experiment with beads containing dark biotin-Mad1:CMad2 and soluble CFP-Mad2. This experiment resulted in 87% 6 8% fluorescence recovery ( Figure 3B and Table 1G). The use of Alexa-Mad2 rather than CFP-Mad2 in the soluble pool did not change significantly the fraction and half-time of recovery (Table 1J) .
Next, we asked whether the Mad1:Mad2 complex isolated from HeLa cells is capable of binding fluorescent Mad2 like its recombinant counterpart. For this, we immobilized a monoclonal anti-Mad1 antibody onto protein G-Sepharose beads and immunoprecipitated the Mad1:Mad2 complex from mitotic HeLa cell extracts (see Experimental Procedures). As a positive control, we first carried out an immunoprecipitation (IP) on the recombinant Mad1:CFP-Mad2 complex. Beads bound to the IPed recombinant Mad1:CFP-Mad2 were used in a control FRAP experiment to show that there is no significant lateral diffusion of the fluorescent protein ( Figure 3C ), presumably because the anti-Mad1 monoclonal antibody binds tightly to Mad1.
Both Mad1 and Mad2 were present in the HeLa IPs ( Figure 3D ). Upon incubation of the Mad1:Mad2 containing beads with recombinant CFP-Mad2, the beads became fluorescent, indicating that CFP-Mad2 recognizes the precipitated complex ( Figure 3E ). Binding of CFPMad2 to the beads was specific, because the addition DC was analyzed by FRAP at the surface of beads containing Mad1:C-Mad2. (D) Alexa-Mad2 was introduced by injection in PtK1 cells and found to localize at kinetochores as described previously [5, 6] . The FRAP experiment shown here reveals that Alexa-Mad2 DC , like Mad2 wt , cycles rapidly at unattached kinetochore in PtK1 cells. Quantification of this experiment is reported in Table 1E. of synthetic peptide encompassing the Mad2 binding region of Cdc20 (Cdc20 ) caused the dissociation of CFP-Mad2 fluorescence from the beads. This confirms that C-Mad2 created upon binding to Cdc20 is unable to bind the C-Mad2 contained in the Mad1: Mad2 IPs. To avoid overinterpretations, however, we wish to clarify that this experiment does not necessarily imply that the binding of O-Mad2 to Cdc20 111-138 requires, or is facilitated by, the Mad1:Mad2 complex on the beads, because it has been shown before that this interaction advances also in the absence of Mad1:Mad2 in vitro [12, 13, 19] . This issue will be discussed more thoroughly later.
An in vitro FRAP experiment was carried out with Mad1 IPs in the presence of CFP-Mad2 ( Figure 3F ). Remarkably, the t 1/2 and percent recovery (3.5 6 1.1 s and 75% 6 8%, respectively; see Table 1H ) were very similar to those measured with the recombinant Mad1:C-Mad2 complex (Table 1G) . Overall, these observations are completely consistent with the hypothesis that a stable Mad1:C-Mad2 kinetochore complex accounts for the observed immobile fractions of Mad1 and Mad2 [7, 19] . comet was added to a medium containing biotin-Mad1:Mad2 bound to streptavidin beads. The FRAP behavior of CFP-p31 comet is displayed. The dataset is described in Table 1L . (E) CFP-Mad2 (15 mM) was incubated with biotin-Mad1:Mad2 (upper panel). After equilibration, unlabeled CFP-p31 comet was added (15 mM). CFPMad2 fluorescence dissociates from the beads (lower panel), indicating that p31 comet competes with O-Mad2 for binding C-Mad2. Figure 3B . Statistics for this experiment are in Table 1N .
(C) CFP-Mad2 (2 mM) was allowed to equilibrate on the Mad1:C-Mad2 substrate. A solution containing 40 mM O-Mad2 DC (or Mad2 wt , Table 1O ) was flowed in the chamber and the dissociation of CFP-Mad2 monitored. The dissociation rates in the presence of 40 mM dark Mad2 wt were essentially identical (data not shown). The dataset is described in Table 1P . (D) The same reaction using all of the above and 40 mM Cdc20 111-138 peptide. The dataset is described in Table 1Q . Mad2 DC was used as dark O-Mad2 in this experiment because this mutant binds Mad1:C-Mad2 but is unable to bind Cdc20, and therefore will not deplete Cdc20 in solution [19] .
This complex, in turn, appears to be responsible for the recruitment of a mobile fraction of O-Mad2 from the cytosol. We suspect that the w10%-20% deviation of the observed recovery values from the expected values in different experiments (see Table 1 ) is caused by photodamage of the receptor-ligand complexes by the high laser power required for photobleaching. We are presently exploring strategies to limit this effect.
Mad2 DC is a Mad2 deletion mutant stably locked in the O-Mad2 conformation and unable to bind Mad1 or Cdc20 [19] . Previously, we have shown that this mutant is able to localize to the kinetochore upon injection in PtK1 cells [19] Figure 4C and Table 1J and 1K), possibly reflecting a marginal contribution of the O-Mad2 C-terminal tail, which is partly deleted in Mad2 DC , to formation of the O-Mad2:C-Mad2 complex. Consistent with these results in vitro, Alexa-Mad2 DC introduced in mitotic PtK1 cells by microinjection cycled at kinetochores with kinetics that were similar to those previously observed when Mad2 wt was used in vivo [5, 6] , but, as for the in vitro case, were slightly faster relative to Mad2 wt ( Figure 4D and Table 1E ).
The overexpression of Mad2 DC has a dominant-negative effect on the SAC [19, 20, 22, 23] . This effect is likely due to the fact that Mad2 DC binds C-Mad2 and competitively inhibits binding of O-Mad2 wt , preventing Mad2 wt from reaching Cdc20. To illustrate this, we bound CFPMad2 to immobilized Mad1:C-Mad2 ( Figure 5A , upper panel). We then added a 2-fold excess of unlabeled Mad2 DC . This readily displaced CFP-Mad2 from the beads ( Figure 5A , lower panel).
Unlike Mad2 DC , which deregulates the SAC nonphysiologically, the Mad2 binding protein p31 comet (previously CMT2) is a physiological negative regulator of the SAC [24, 25] . The observation that p31 comet binds selectively to C-Mad2 and does not bind O-Mad2 prompted the suggestion that p31 comet might prevent C-Mad2 from sequestering Cdc20 [25] . In contradiction to this expectation, however, p31 comet was found to bind tightly to the Cdc20:C-Mad2 complex without affecting its stability [25] , so p31 comet must function in a different way.
Because C-Mad2 is present both in the Mad1:C-Mad2 and in the Cdc20:C-Mad2 complexes, p31 comet , which has been previously shown to bind Cdc20:C-Mad2 [25] , is also predicted to bind Mad1:C-Mad2. Indeed, CFP-p31 comet formed a tight complex with Mad1:CMad2 ( Figures 5B and 5C ), whose dissociation constant (K D ) by ITC was w25 nM (Table 2B ). In agreement with its tight binding, CFP-p31 comet cycled on the Mad1:C-Mad2 complex with a half-time of recovery of 20 s, indicative of a slower rate of dissociation relative to w4 s half-life of Mad2. The percent recovery was w90% ( Figure 5D and Table 1L ).
The Mad2 template model [19, [26] [27] [28] suggests an alternative hypothesis for understanding the function of p31 Cdc20 cycles rapidly at kinetochores [5] [6] [7] [8] . Whether this cycle reflects its capture by Mad2 is currently unclear. Conversely, it is unknown whether the Mad2 cycle on kinetochores is influenced by Cdc20, the protein to which Mad2 is expected to bind at kinetochores. In this respect, it is interesting to note that Mad2 DC , which does not bind Cdc20 [19, 21] , cycled on C-Mad2 in vitro and in vivo with a turnover rate similar to that of Mad2 wt (Table 1D , 1E, 1J, and 1K and Figure 4 ). This implies that Cdc20 does not influence the turnover rate of kinetochore Mad2, suggesting that Mad2 is released from kinetochores before it binds Cdc20. An alternative explanation, however, is that only a small fraction of O-Mad2 cycling on Mad1:C-Mad2 at kinetochores is removed by Cdc20, too small to be observed in the Mad2 FRAP curves in vivo.
To shed light on this issue, we developed an implementation of our recruitment assay allowing continuous imaging of a surface containing immobilized Mad1:CMad2 while being perfused with a solute. Biotinylated nonfluorescent Mad1:C-Mad2 was immobilized on the bottom surface of a flow cell connected to a peristaltic pump. CFP-Mad2 was injected, and the flow was stopped to allow equilibration. CFP-Mad2 bound readily to the surface containing the Mad1:C-Mad2 receptor. If (E) We speculate that the recruitment of the Mad1:C-Mad2 complex to an unattached kinetochore results in the inactivation of p31 comet and its fast release from kinetochores. Note that p31 comet may undergo a continuous cycle of inactivation at unattached kinetochores similar to the Mad2 activation cycle. An unknown kinetochore function (green ball with question mark) inactivates p31 comet . (F) Cytosolic Mad2 has the O-Mad2 conformation [19, 20] . The Mad1:C-Mad2 complex recruits O-Mad2 to kinetochores, and O-Mad2 is converted into C-Mad2 bound to Cdc20. Mad2:Cdc20 is a structural copy of Mad1:Mad2, because Mad1 and Cdc20 share a Mad2 binding motif, and Mad2 adopts the same C-Mad2 conformation in these complexes. The ''Mad2 template'' model [19] predicts that C-Mad2:Cdc20 is a structural equivalent of Mad1:Mad2 and converts more O-Mad2 into Cdc20-bound C-Mad2, possibly creating a positive feedback module for amplification of the SAC signal. (G) After microtubule attachment, Dynein removes Mad1:C-Mad2 from kinetochores [10] . Mad1:Mad2 is thus separated from the kinetochore function that inactivates p31
comet . This eventually leads to the reactivation of p31 comet , which acts as a ''screen'' that interposes itself.
the same experiment was carried out in the presence of the Cdc20 111-138 synthetic peptide, CFP-Mad2 did not accumulate on the surface, confirming that binding is specific for O-Mad2 ( Figure 6A ). To assess the dynamic properties of Mad2 in this new system, we performed a FRAP experiment similar to that shown in Figure 3B . The half-time and fraction of recovery were very similar to those obtained on beads ( Figure 6B and Table 1N ).
To assess whether Cdc20 accelerates the removal of OMad2 from the Mad1:C-Mad2 complex, we carried out an ''off rate'' experiment ( Figure 6C ). CFP-Mad2 (2 mM) was equilibrated on the immobilized Mad1:Mad2 complex. We monitored the dissociation of CFP-Mad2 from the Figure 6C , data not shown, and Table 1O and 1P). Next, we repeated this experiment after adding Cdc20 (at 40 mM) together with the same excess of dark O-Mad2 DC . The dissociation curve was fitted with a single exponential function with a halftime of dissociation essentially identical to that measured in the absence of Cdc20 ( Figure 6D and Table  1Q ). These results indicate that Cdc20 does not influence the turnover of kinetochore Mad2, at least in the absence of a Cdc20 binding site near the Mad1:C-Mad2 complex.
Discussion
Our in vitro FRAP analysis recapitulates faithfully the results of previous FRAP analyses of Mad2 carried out in living cells [5] [6] [7] . The analysis provides a straightforward explanation of the differences in percent recoveries between experiments in which transient expression or protein injection of fluorescent Mad2 was used, reporting near to full recovery of kinetochore Mad2 fluorescence [5, 6] , as opposed to experiments using stable YFPMad2 expression and reporting 50% recovery [7] . The most likely explanation of these discrepancies is that the stability of the Mad1:C-Mad2 complex prevents the binding of the fluorescent Mad2 species to Mad1, unless a long-term expression strategy is adopted, as was the case for the experiments using stable YFPMad2 cell lines. This interpretation is confirmed by the fact that the percent recovery of Alexa-Mad2 DC injected into PtK1 cells is also near 100% (Figure 4 and Table 1E ), as it is for Alexa-Mad2 wt [5, 6] . Because Mad2 DC is unable to bind Mad1 whereas Mad2 wt is in principle able to do it, the fact that both constructs provide the same fraction of recovery suggests that there is not enough time for fluorescent Mad2 wt to bind Mad1 in these experiments. Consistent with this prediction, if the FRAP experiment in vitro was carried out with unlabeled Mad1: Mad2 complex, near to 90% recovery was observed ( Figure 3B and Table 1G ). This underscores the accuracy with which in vitro FRAP might provide detailed molecular accounts of dynamic live-cell measurements.
So far, the studies in living cells have reported somewhat different half-times of recovery, ranging between 6 and 25 s (Table 1A-1D) . Different camera acquisition rates, sensitivities, and phototoxicity might all affect the initial part of the recovery curve and provide somewhat different accounts of the times of recovery. In vitro, we have consistently measured a half-time of w3-5 s for the Mad2 cycle (Table 1 ). This value is not more dissimilar from the in vivo data than the in vivo measurements among themselves. At present, we are unable to provide a certain explanation for the observed discrepancy. We note that it is possible that the slightly faster half-times observed in vitro might reflect modulations of the affinity of the interaction of the Mad1:C-Mad2 receptor for O-Mad2 in vivo. In particular, a decreased half-time (that is, a faster k off ) implies (assuming an identical k on ) a decrease in the affinity of the interaction. It is possible that additional interactions, such as for instance additional van der Waals contacts or additional hydrogen bonds, provide an increased binding energy to the interaction. If existing, however, these effects must be minimal because a 2-to 5-fold change in k off would only predict a linear 2-to 5-fold change in the K D of the interaction. We also note that in cellular FRAP experiments carried out so far, the fluorescent species coexisted with endogenous nonfluorescent molecules. Thus, dark endogenous molecules might compete with fluorescent ones so that the apparent recovery will appear slower than it would be in the absence of dark competitors.
Our results show unequivocally that the Mad1:CMad2 complex does not dissociate during mitosis [7, 19] . The implication of this is that the two pools of Mad2, the C-Mad2 pool bound to Mad1 and the cytosolic O-Mad2 pool destined to Cdc20, are distinct and nonexchanging. Furthermore, this implies that the molecules of Mad2 eventually destined to bind Cdc20 are drafted exclusively from the cytosolic pool. The interaction of these two genetically identical but conformationally dissimilar pools in the O-Mad2:C-Mad2 complex is a striking characterizing element of the Mad2 checkpoint and bears clear resemblances-in addition to important differences-with prion proteins [29] .
Our experiments also suggest that Cdc20 does not influence the rate of dissociation of ''external'' Mad2 from its complex with Mad1:C-Mad2 ( Figure 6 ). A possible caveat with these experiments is that they were carried out with a short segment of Cdc20, and we cannot exclude that the missing segments of Cdc20 are important to accelerate the dissociation of Mad2 from the Mad1:Mad2 complex. Future mechanistic studies on how the interaction of O-Mad2 with C-Mad2 fosters the interaction with Cdc20 will have to address the actual conformation of Mad2 dissociating from Mad1:Mad2. For this, we envision that a real-time sensor of Mad2 conformation will need to be developed.
Although Mad2 is able to bind Cdc20 in vitro in the absence of other proteins, the interaction is slow. For instance, the binding of O-Mad2 to a synthetic peptide encompassing the Cdc20 sequence has an association rate (k on ) in the range of 10 2 M 21 s 21 (M.V. and A.M., unpublished data). A slow rate of association is expected if one considers the extent of the conformational change O-Mad2 needs to undergo to bind Cdc20 turning into C-Mad2. We suspect that the significance of the interaction of O-Mad2 with C-Mad2 is to accelerate this structural conversion, possibly explaining the catalytic role played by unattached kinetochores (i.e., Mad1:C-Mad2) in generating the checkpoint signal.
It is also intriguing that the intrinsic properties of the interaction between the two pools of Mad2 and its regulation by p31 comet appear to be largely sufficient for explaining the kinetochore cycle of Mad2. Our results delineate a model predicting that kinetochores cause the inactivation of p31 comet and its release from Mad1: C-Mad2 to allow kinetochore recruitment of O-Mad2 (Figures 6E-6G) . The latter might be modified at kinetochores and released in an activated form that binds rapidly to Cdc20. Microtubule attachment results in the depletion of Mad1 and Mad2 from kinetochores [10] , and this may coincide with the reactivation of p31 comet and subsequent inhibition of the O-Mad2:C-Mad2 interaction. The ''Mad2 template'' model predicts a direct catalytic role of C-Mad2 on the transformation of O-Mad2 to C-Mad2 bound to Cdc20. Testing this prediction is clearly essential for validating the model.
Conclusions
A proper understanding of the molecular network responsible for the spindle checkpoint requires a systems approach, based upon law of mass action and mathematical modeling [3, 4] . Oftentimes kinetic models are underdetermined because experimental values for rate constants and concentration are lacking. In vitro FRAP and the other approaches reported here can contribute to solving this major shortcoming of the modeling approach. In particular, we show in Supplemental Experimental Procedures that combining in vitro FRAP with a measure of K D allows the estimation of both kinetic parameters (k on and k off ) of an interaction. The procedure is completely general and may be extended to the study of virtually any macromolecular interaction.
Experimental Procedures
Protein Expression, Covalent Modifications of Proteins, and Immunoprecipitations Readers are referred to the Supplemental Experimental Procedures section in the Supplemental Data.
In Vitro FRAP, Beads Implementation Agarose beads with immobilized streptavidin (SIGMA, S1638) were washed and equilibrated in PBS. Purified biotin-Mad1:CFP-Mad2 or biotin-Mad1:Mad2 were added at streptavidn:biotin ratio of w32:1 and incubated for 1 hr at 4ºC. Beads with immobilized Mad1:Mad2 were washed with PBS and stored at 280ºC until use. FRAP measurements were performed on a Leica TCS SP2 confocal microscope equipped with a 633/1.40 (OIL CS HC3PL APO) objective lens (Leica). Streptavidin-agarose beads containing w10 pmoles of immobilized Mad1/Mad2 core complexes were typically mixed in a chambered coverglass well (Lab-Tek II) with 1500 pmoles external ligand (Mad2 or p31 comet ) in a final volume of 100 ml PBS, yielding molar concentrations of 0.1 mM and 15 mM, respectively. External ligand concentrations of 15 mM and above were found to saturate kinetics and to yield reproducible results. Imaging was controlled by Leica Confocal Software (v. 2.61), and photobleaching was carried out with the 488 nm line (Alexa-488) and the 458 nm line (CFP) of an Ar/ArKr laser at 20 mW. An area with an approximate diameter of 10 mm at the edge of a bead was bleached, and images were collected with a temporal resolution of 115 ms between frames. ImageJ software was used to calculate mean pixel intensities of bleached areas with time, and the values were exported to an Excel spreadsheet. Recovery percentage was taken as the final average plateau intensity (F N ) minus the fluorescence immediately after photobleaching (F 0 ), all divided by the difference between prebleach (F I ) and postbleach intensities [(F N 2 F 0 )/(F I 2 F 0 )]. The exponential kinetics of FRAP was analyzed by calculating the normalized unrecovered fluorescence at each time-point [(F N 2 F t )/(F N 2 F 0 )]. Recovery half-times (t 1/2 ) were calculated according to t 1/2 = ln(2)/k, where k is the time constant for a single-exponential recovery model [30] . For ensuring possible artifact of photobleaching, the mean pixel intensities of the areas on the beads surrounding the bleached area were monitored. If photobleaching occurred (<95% of original value at the end of the experiment), or if the bead moved during analysis, that particular measurement was excluded. All recovery measurements displayed single exponential recovery kinetics.
In Vitro FRAP, Flat Surface Twenty-five microliters flow cells (m-slide VI Flow-trough, Ibidi GmbH, Munich, Germany) were coated with streptavidin essentially as described [31] . The flow cell was injected with the following reagents in subsequent steps: 30 ml of 2.5 mg/ml Biotin-BSA (Pierce, ImmunoPure Biotin-LC-BSA, #29130) dissolved in MilliQ water, 30 ml 1 mg/ml NeutrAvidin (Molecular Probes, A-2666) in TRIS-EDTA buffer, and 30 ml 5 mg/ml BSA (A-9085 Sigma) in MilliQ water. Each incubation was protracted for 30 min. After a washing step with MilliQ water (53 chamber volume), the flow cell was equilibrated with PBS. After this, 30 ml of 1 mM purified biotin-Mad1:Mad2 complex in PBS was added and incubated for 30 min. Finally, the cells were washed with 125 ml PBS. In vitro FRAP experiments were performed with 2 mM external CFP-Mad2 equilibrated with immobilized biotin-Mad1:Mad2. Photobleaching, data acquisition, and analysis were performed as described above for the beads assay.
In Vivo FRAP FRAP experiments on kinetochore-bound Alexa-Mad2 DC and AlexaMad2 wt in PtK1 cells were carried out precisely as described before [5, 6] . The quantification of these experiments is reported in Table 1 .
Dissociation Rates
Imaging of dissociation experiments was carried out with a temporal resolution of 0.15 s. The reaction was first driven to equilibration by using 2 mM CFP-Mad2 on the immobilized biotin-Mad1:Mad2. Dissociation was filmed while 50 ml of a 40-fold excess of O-Mad2 was injected at a flow rate of 25 ml/s. The images were analyzed with ImageJ software, and the data were exported to an Excel spreadsheet for analysis. 
